

**SUGGESTED FORMULA**

Hydroquinone 4% / Retinoic Acid 0.1% / Triamcinolone Acetonide 0.025% / Vitamin E 1.75% in Niosome Cream

Version number: 1.0

Volume or quantity: 100 gm

---

Hydroquinone, USP (HY113)	4 gm
Retinoic Acid, USP (R1022)	0.10 gm
Triamcinolone Acetonide, USP (TR107)	0.025 gm
Vitamin E Acetate, USP (VI140)	1.75 gm
Butylated Hydroxytoluene, NF (B1196)	0.40 gm
Castor Oil, USP (CA208)	4.5 gm
Polysorbate 80, NF (PO138)	1 gm
Propylene Glycol, USP (PR130)	8 mL
Sodium Ascorbate, USP (S1349)	3 gm
Citric Acid, Anhydrous, USP (CI131)	3 gm
Base, Niosome Hormone Cream (B4504)	QS 100gm

---

**SUGGESTED COMPOUNDING PROCEDURES**

1. Calculate the required quantity of each ingredient for the total amount to be prepared
2. Accurately weigh and/or measure each ingredient
3. Triturate the retinoic acid and triamcinolone with a small quantity of propylene glycol to wet the powders
4. Add the hydroquinone powder and mix until all are dissolved
5. Incorporate the sodium ascorbate and citric acid and mix well
6. Add the butylated hydroxytoluene, polysorbate 80, castor oil and vitamin E acetate and mix until homogenous
7. Incorporate the niosome cream base and mix until smooth and homogenous
8. Package and Label. Keep tightly closed and refrigerated
9. Suggested Quality assessments:
  - a. color
  - b. texture
  - c. container
  - d. Label - auxiliary labels, storage, BUD, compounded medication

**\*Warning\*** Pregnant woman must not handle this medication

Store in light resistant air-tight container. Refrigerate.

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use-Dates of preparations are conservative estimates from reference books, peer-reviewed literature, and intended duration of therapy, formulation from commercially available products, organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date. It is recommended that you follow USP <795> recommendations for potency testing.

Beyond-Use-Date should be assigned based on the current USP <795>.

Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate protective equipment. Use safety enclosures (hoods) when weighing and mixing.

Although much attention has been paid to ensure the accuracy of the formulation contained here, Spectrum Pharmacy Products accepts no liability for the loss or damage arising from reliance on the information. Compounding pharmacists using this formula take full responsibility for the formulations and hold Spectrum Pharmacy Products and Spectrum Chemical Mfg Corp. and its officers, directors and employees harmless for any claim arising from use of or reliance on information contained therein.

8/19 mc